Galimedix is focusing on the development of GAL-101 eye drops for neuroprotective therapy to slow progression of glaucoma and dry AMD, both being neurodegenerative diseases of the eye. GAL-101 and 201 were each designed to prevent formation of toxic oligomers of amyloid beta, and GAL-201 may also be directed to central nervous system (CNS) diseases such as Alzheimer's disease. Galimedix intends to first develop its drug in the eye, where it takes advantage of the benefits of eye drop administration established study endpoints to read out the effect of treatment and addresses large markets of unmet need. Proof of concept for the target and mechanism of action in the eye will also support use in Alzheimer's disease and other indications moving forward.